Indian Journal of Clinical Biochemistry

, Volume 34, Issue 4, pp 458–464 | Cite as

Evaluating NISCH and CDH1 Promoter Hypermethylation in Nonsmokers, Cancer Free Smokers and Lung Cancer Patients: A Case Control Study

  • Kritika KrishnamurthyEmail author
  • T. K. Mishra
  • Alpana Saxena
  • M. K. Daga
  • Nita Khurana
  • Mirza Masroor
  • Elvia Jamatia
Original Research Article


Lung cancer has very high mortality due to late stage diagnosis not amenable to curative resection. Cancer specific methylation patterns of tumor suppressor genes may precede precursor lesions of lung cancer. Our aim was to evaluate the promoter hypermethylation of tumor suppressor gene NISCH and CDH1 in cfDNA from plasma of lung cancer patients and its possible correlation with smoking status and various clinicopathological parameters. Forty histopathologically confirmed lung cancer cases, thirty smoker and thirty nonsmoker controls were enrolled. Plasma cfDNA was extracted and subjected to bisulfite treatment followed by MS-PCR. Serum nischarin levels were estimated by ELISA. The frequency of promoter hypermethylation of NISCH and CDH1 was significantly higher in lung cancer patients as compared to lifelong non-smoker controls (p < 0.05). It did not vary with smoking status among cancer cases. No significant association was found with staging or histological grading. NISCH methylation was found to be significantly higher among smoker controls. Pack years and packs per day were significantly higher in the methylated group. Serum nischarin levels showed no significant association with NISCH methylation or clinicopathological variables. NISCH is highly methylated in both high risk smoker controls as well as cancerousnon-smokers and may mark the convergence of varied etiologies of lung cancer. Hence NISCH and CDH1 are highly methylated in plasma cfDNA of lung cancer patients.


NISCH CDH1 Hypermethylation ccfDNA Epigenetics 



We acknowledge Dr. Sudhesna Mohapatra, Dr. Kajal Tanwer, Mr. Prashant Yadav and Ms. Mariyam Zuberi for their guidance.

Author Contributions

Conception and design: KK, TKM and AS; Administrative support: MKD, NK; Provision of study materials or patients: MKD, NK; Collection and assembly of data: KK, MM, EJ; Data analysis and interpretation: KK, MM; Manuscript writing: All authors.; Final approval of manuscript: All authors.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by institutional ethics committee.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(2010):2893–917.CrossRefGoogle Scholar
  2. 2.
    Horn L, Pao W, Johnson D. Neoplasms of the lung Harrison’s principles of internal medicine. 18th ed. New York: Mcraw Hill Medical; 2012. p. 737–53.Google Scholar
  3. 3.
    Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003;3:733–44.CrossRefGoogle Scholar
  4. 4.
    Doll R, Hill A. Smoking and carcinoma of the lung. BMJ. 1950;2(4682):739–48.CrossRefGoogle Scholar
  5. 5.
    Lu C, Onn A, Vaporciyan A. Cancer of the lung. In: Hong W, Blast R, Hait W, Kufe D, editors. Holland-Frei cancer medicine. 8th ed. Raleigh: People’s Medical Publishing House; 2010. p. 990–1043.Google Scholar
  6. 6.
    Ries L, Kosary C, Hankey B, Miller B, Clegg L, Edwards B. SEER cancer statistics review, 1973–1996: tables and graphs. Bethesda (MD): US Dept. of Health and Human Services. Rockville: Public Health Service, NM, National Cancer Institute; 1999. p. 42.Google Scholar
  7. 7.
    Ostrow K, Hogue M, Loyo M, Brait M, Greenberg A, Siegfried J, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 2010;16(13):3463–72.CrossRefGoogle Scholar
  8. 8.
    Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011;17(13):4494–503.CrossRefGoogle Scholar
  9. 9.
    Ostrow KL, Michailidi C, Guerrero-Preston R, Hogue MO, Greenberg A, Rom W, et al. Cigarette smoke induces methylation of the tumor suppressor gene NISCH. Epigenetics. 2013;8(4):383–8.CrossRefGoogle Scholar
  10. 10.
    Li J, He X, Wan Y, Yu J, Qiu H. Frequent loss of NISCH promotes tumor proliferation and invasion in ovarian cancer via inhibiting the FAK signal pathway. Mol Cancer Ther. 2015;14(5):1–11.CrossRefGoogle Scholar
  11. 11.
    Alahari SK. Mapping of the gene for Nischarin, a novel integrin binding protein, to chromosome 3 by fluorescence in situ hybridization. Int J Hum Genet. 2001;1(4):271–4.CrossRefGoogle Scholar
  12. 12.
    Varner JA, Emerson DA, Juliano RL. Integrin α5β1 expression negatively regulates cell growth reversal by attachment to fibronectin. Mol Biol Cell. 1995;6:725–40.CrossRefGoogle Scholar
  13. 13.
    Chen J, Feng WL, Mo WJ, Ding XW, Xie SN. Expression of integrin-binding protein Nischarin in metastatic breast cancer. Mol Med Rep. 2015;12(1):77–82.CrossRefGoogle Scholar
  14. 14.
    Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18(5):1225–30.PubMedGoogle Scholar
  15. 15.
    Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, et al. RASSF1A and CDH1 hypermethylation as potential epimarkersin breast cancer. Cancer Biomark. 2011;10(1):13–26.CrossRefGoogle Scholar
  16. 16.
    Melnikov A, Shrestha S, Yi Q, Replogle C, Borgia J, Bonomi P, et al. Non-small cell lung cancer can be detected and its subtypes differentiated by a blood test of methylation in cell-free DNA from plasma. JSM Biomark. 2014;1(1):1003–11.Google Scholar
  17. 17.
    Caldeira JRF, Prando ÉC, Quevedo FC, Neto FAM, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer. 2006;6:48. Scholar

Copyright information

© Association of Clinical Biochemists of India 2018

Authors and Affiliations

  • Kritika Krishnamurthy
    • 1
    Email author
  • T. K. Mishra
    • 1
  • Alpana Saxena
    • 1
  • M. K. Daga
    • 2
  • Nita Khurana
    • 3
  • Mirza Masroor
    • 1
  • Elvia Jamatia
    • 1
  1. 1.Department of BiochemistryMaulana Azad Medical CollegeNew DelhiIndia
  2. 2.Department of MedicineMaulana Azad Medical CollegeNew DelhiIndia
  3. 3.Department of PathologyMaulana Azad Medical CollegeNew DelhiIndia

Personalised recommendations